NCT04919382 2026-04-08
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
Clinical Trials
9 trialsNCT03830918 2026-02-12
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03672773 2025-11-10
TRIO-US L-07
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02446704 2022-02-07
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Massachusetts General Hospital
Phase 1/2 Unknown
NCT02605811 2019-03-28
Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
Guangzhou Medical University
Phase 2 Unknown
NCT02772107 2016-05-17
Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer
Chinese PLA General Hospital
Phase 2/3 Unknown
NCT01900951 2016-01-26
Temozolomide as Maintenance Therapy in Small Cell Lung Cancer
Chinese PLA General Hospital
Phase 2 Unknown
NCT00022711 2013-07-11
Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer
Fox Chase Cancer Center
Phase 2 Completed